Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AVC-201 |
| Synonyms | |
| Therapy Description |
AVC-201 (Allo-RevCAR01-T-CD123) comprises an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a universal switchable CAR targeting CD123, which potentially induces killing of tumor cells expressing CD123 (Cancer Res (2023) 83 (7_Supplement): 4095). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AVC-201 | AVC 201|AVC201 | AVC-201 (Allo-RevCAR01-T-CD123) comprises an allogeneic chimeric antigen receptor (CAR) T-cell therapy containing a universal switchable CAR targeting CD123, which potentially induces killing of tumor cells expressing CD123 (Cancer Res (2023) 83 (7_Supplement): 4095). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05949125 | Phase I | Cyclophosphamide + Fludarabine AVC-201 | Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | Recruiting | NLD | DEU | 0 |